Articles about Celgene

Juno’s lasting legacy: How the cell therapy juggernaut influenced biotech in Seattle and beyond

When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of… Read More

Bristol Myers Squibb exec on the company’s growth in Seattle and beating cancer with immune cells

Pharmaceutical giant Bristol Myers Squibb has been quietly growing in the Seattle area. Since acquiring Celgene and its Seattle operations… Read More

Bristol-Myers deal to acquire Juno parent Celgene delayed amid FTC concerns

The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a… Read More

Bristol-Myers Squibb exec on how can Seattle grow — and keep — big biotech companies

Henrik Andersen, head of biologics development at Bristol-Myers Squibb, knows what it’s like to be at a hot biotech when… Read More

Bristol-Myers Squibb’s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert

Things are a little on edge in Seattle’s biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb… Read More

Celgene CEO: Treating cancer is becoming ‘ironically easy’ — now the problem is affordability

BELLEVUE, Wash. — Cancer treatments have improved astronomically in the past few decades. But as more patients overcome the disease,… Read More

Longtime Juno Therapeutics CEO Hans Bishop leaves role after acquisition by Celgene

Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s… Read More

Why we’re in a ‘different era’ of cancer research, and where things go from here

Four decades ago, the overall chance of someone surviving cancer was about 50-50— not exactly a promising outlook. Today, those… Read More

Why Celgene decided to buy Juno Therapeutics for $9B — with a little help from U.S. tax reform

When Celgene announced Monday that it will acquire Seattle-based biotech Juno Therapeutics for $9 billion, the development was a surprise… Read More

Juno Therapeutics acquired by Celgene for $9B in dramatic deal for rising biotech star

Juno Therapeutics, the Seattle-based biotech company making cutting-edge cancer immunotherapy treatments, has reached a deal to be acquired by New Jersey-based… Read More

Juno stock skyrockets after Celgene invests $1 billion to change the way cancer is treated

Shares of Seattle-based biotech startup Juno Therapeutics spiked more than 60 percent in after-hours trading on Monday after the company announced… Read More